CAR T cell (English Wikipedia)

Xu, Jun; Nunez-Cruz, Selene; Leferovich, John M.; Gulendran, Gayathri; Zhang, Chune; Yucel, Nora D.; Blair, Megan C.; Stanley, William S.; Johnson, Laura A.; Siegel, Don L.; Milone, Michael C. (2024-03-22). "Abstract 6332: Evaluating the relationship of affinity, functional avidity, and in vivo potency in KIR-CAR T cells". Cancer Research. 84 (6_Supplement): 6332. doi:10.1158/1538-7445.AM2024-6332. ISSN 1538-7445.

ashpublications.org

Gust, Juliane (October 5, 2023). "BCMA-CAR T-cell treatment–associated parkinsonism". Blood. 142 (14): 1181–1183. doi:10.1182/blood.2023021860. PMID 37796518. Retrieved April 4, 2024.

bms.com

news.bms.com

"U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma". news.bms.com. Retrieved 2023-11-21.
"CAR T Cell Therapy Breyanzi® Approved as Relapsed or Refractory Large B-cell Lymphoma Second-Line Therapy in Japan". new.bms.com.

cgtlive.com

"First-in-Human Trial to Assess KIR-CAR T-Cell Therapy in MSLN+ Solid Tumors". CGTlive™. 2022-09-25. Retrieved 2024-06-05.

clinicaltrials.gov

"Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)". ClinicalTrials.gov. Retrieved 2018-02-21.

cms.gov

"Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)". www.cms.gov. Retrieved 2021-03-22.

creativecommons.org

Chandran SS, Klebanoff CA (July 2019). "T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance". Immunological Reviews. 290 (1): 127–147. doi:10.1111/imr.12772. PMC 7027847. PMID 31355495. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.

doi.org

Srivastava S, Riddell SR (August 2015). "Engineering CAR-T cells: Design concepts". Trends in Immunology. 36 (8): 494–502. doi:10.1016/j.it.2015.06.004. PMC 4746114. PMID 26169254.
Sadelain M, Brentjens R, Rivière I (April 2013). "The basic principles of chimeric antigen receptor design". Cancer Discovery. 3 (4): 388–398. doi:10.1158/2159-8290.CD-12-0548. PMC 3667586. PMID 23550147.
Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ (September 2017). "Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts". EMBO Molecular Medicine. 9 (9): 1183–1197. doi:10.15252/emmm.201607485. PMC 5582407. PMID 28765140.
Tang XJ, Sun XY, Huang KM, Zhang L, Yang ZS, Zou DD, et al. (December 2015). "Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy". Oncotarget. 6 (42): 44179–44190. doi:10.18632/oncotarget.6175. PMC 4792550. PMID 26496034.
Zhang H, Zhao P, Huang H (December 2020). "Engineering better chimeric antigen receptor T cells". Experimental Hematology & Oncology. 9 (1): 34. doi:10.1186/s40164-020-00190-2. PMC 7709221. PMID 33292660.
Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. (December 1987). "Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions". Biochemical and Biophysical Research Communications. 149 (3): 960–968. doi:10.1016/0006-291x(87)90502-x. PMID 3122749.
Rosenbaum L (October 2017). "Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy". The New England Journal of Medicine. 377 (14): 1313–1315. doi:10.1056/NEJMp1711886. PMID 28902570. S2CID 205114161.
Gross G, Waks T, Eshhar Z (December 1989). "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity". Proceedings of the National Academy of Sciences of the United States of America. 86 (24): 10024–10028. Bibcode:1989PNAS...8610024G. doi:10.1073/pnas.86.24.10024. JSTOR 34790. PMC 298636. PMID 2513569.
Eshhar Z, Bach N, Fitzer-Attas CJ, Gross G, Lustgarten J, Waks T, Schindler DG (1996). "The T-body approach: potential for cancer immunotherapy". Springer Seminars in Immunopathology. 18 (2): 199–209. doi:10.1007/BF00820666. PMID 8908700. S2CID 19872173.
Irving BA, Weiss A (March 1991). "The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways". Cell. 64 (5): 891–901. doi:10.1016/0092-8674(91)90314-o. PMID 1705867. S2CID 23466990.
Hege KM, Roberts MR (December 1996). "T-cell gene therapy". Current Opinion in Biotechnology. 7 (6): 629–634. doi:10.1016/s0958-1669(96)80074-7. PMID 8939644.
June CH, Sadelain M (July 2018). "Chimeric Antigen Receptor Therapy". The New England Journal of Medicine. 379 (1): 64–73. doi:10.1056/NEJMra1706169. PMC 7433347. PMID 29972754.
Braendstrup P, Levine BL, Ruella M (February 2020). "The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19". Cytotherapy. 22 (2): 57–69. doi:10.1016/j.jcyt.2019.12.004. PMC 7036015. PMID 32014447.
Sadelain M, Rivière I, Brentjens R (January 2003). "Targeting tumours with genetically enhanced T lymphocytes". Nature Reviews. Cancer. 3 (1): 35–45. doi:10.1038/nrc971. PMID 12509765. S2CID 33707802.
Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M (2014-03-05). "Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors". Molecular Therapy: Methods & Clinical Development. 1: 14001. doi:10.1038/mtm.2014.1. PMC 4362340. PMID 26015949.
Li, Nan; Ho, Mitchell (2022). "Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma". Single-Domain Antibodies. Methods in Molecular Biology. Vol. 2446. pp. 451–468. doi:10.1007/978-1-0716-2075-5_23. ISBN 978-1-0716-2074-8. ISSN 1940-6029. PMID 35157288. S2CID 246813053.
Makita S, Yoshimura K, Tobinai K (June 2017). "Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma". Cancer Science. 108 (6): 1109–1118. doi:10.1111/cas.13239. PMC 5480083. PMID 28301076.
Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D (July 2016). "Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer". EMBO Molecular Medicine. 8 (7): 702–711. doi:10.15252/emmm.201505869. PMC 4931286. PMID 27189167.
Jensen TI, Axelgaard E, Bak RO (June 2019). "Therapeutic gene editing in haematological disorders with CRISPR/Cas9". British Journal of Haematology. 185 (5): 821–835. doi:10.1111/bjh.15851. PMID 30864164.
Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP (December 2006). "Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?". Nature Clinical Practice. Oncology. 3 (12): 668–681. doi:10.1038/ncponc0666. PMC 1773008. PMID 17139318.
Xin Yu J, Hubbard-Lucey VM, Tang J (October 2019). "The global pipeline of cell therapies for cancer". Nature Reviews. Drug Discovery. 18 (11): 821–822. doi:10.1038/d41573-019-00090-z. PMID 31673124. S2CID 190862546.
Almåsbak H, Aarvak T, Vemuri MC (2016). "CAR T Cell Therapy: A Game Changer in Cancer Treatment". Journal of Immunology Research. 2016: 5474602. doi:10.1155/2016/5474602. PMC 4889848. PMID 27298832.
Jacobson CA, Ritz J (November 2011). "Time to put the CAR-T before the horse". Blood. 118 (18): 4761–4762. doi:10.1182/blood-2011-09-376137. PMID 22053170.
Li, Nan; Spetz, Madeline R.; Li, Dan; Ho, Mitchell (July 2021). "Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3". Pharmacology & Therapeutics. 223: 107892. doi:10.1016/j.pharmthera.2021.107892. ISSN 1879-016X. PMC 8202769. PMID 33992682.
Li, Dan; Lin, Shaoli; Hong, Jessica; Ho, Mitchell (2022). "Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances". Advances in Cancer Research. 156: 415–449. doi:10.1016/bs.acr.2022.01.013. ISBN 9780323983921. ISSN 2162-5557. PMID 35961708. S2CID 246978004.
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. (November 2010). "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19". Blood. 116 (20): 4099–4102. doi:10.1182/blood-2010-04-281931. PMC 2993617. PMID 20668228.
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. (February 2015). "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor". Journal of Clinical Oncology. 33 (6): 540–549. doi:10.1200/JCO.2014.56.2025. PMC 4322257. PMID 25154820.
Schultz L, Mackall C (February 2019). "Driving CAR T cell translation forward". Science Translational Medicine. 11 (481): eaaw2127. doi:10.1126/scitranslmed.aaw2127. PMID 30814337.
Choi, Bryan D.; Gerstner, Elizabeth R.; Frigault, Matthew J.; Leick, Mark B.; Mount, Christopher W.; Balaj, Leonora; Nikiforow, Sarah; Carter, Bob S.; Curry, William T.; Gallagher, Kathleen; Maus, Marcela V. (2024-04-11). "Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma". New England Journal of Medicine. 390 (14): 1290–1298. doi:10.1056/NEJMoa2314390. ISSN 0028-4793. PMC 11162836. PMID 38477966.
Lim WA, June CH (February 2017). "The Principles of Engineering Immune Cells to Treat Cancer". Cell. 168 (4): 724–740. doi:10.1016/j.cell.2017.01.016. PMC 5553442. PMID 28187291.
Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, et al. (June 2020). "Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice". Gastroenterology. 158 (8): 2250–2265.e20. doi:10.1053/j.gastro.2020.02.011. PMC 7282931. PMID 32060001.
Li, Nan; Fu, Haiying; Hewitt, Stephen M.; Dimitrov, Dimiter S.; Ho, Mitchell (2017-08-08). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America. 114 (32): E6623–E6631. Bibcode:2017PNAS..114E6623L. doi:10.1073/pnas.1706055114. ISSN 1091-6490. PMC 5559039. PMID 28739923.
Li, Nan; Torres, Madeline B.; Spetz, Madeline R.; Wang, Ruixue; Peng, Luyi; Tian, Meijie; Dower, Christopher M.; Nguyen, Rosa; Sun, Ming; Tai, Chin-Hsien; de Val, Natalia; Cachau, Raul; Wu, Xiaolin; Hewitt, Stephen M.; Kaplan, Rosandra N. (2021-06-15). "CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice". Cell Reports. Medicine. 2 (6): 100297. doi:10.1016/j.xcrm.2021.100297. ISSN 2666-3791. PMC 8233664. PMID 34195677.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M (May 2008). "Regulatory T cells and immune tolerance". Cell. 133 (5): 775–787. doi:10.1016/j.cell.2008.05.009. PMID 18510923. S2CID 2315895.
Zhang Q, Lu W, Liang CL, Chen Y, Liu H, Qiu F, Dai Z (2018). "Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance". Frontiers in Immunology. 9: 2359. doi:10.3389/fimmu.2018.02359. PMC 6194362. PMID 30369931.
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. (August 2021). "CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus". The New England Journal of Medicine. 385 (6): 567–569. doi:10.1056/NEJMc2107725. PMID 34347960. S2CID 236927691.
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016). "Toxicity and management in CAR T-cell therapy". Molecular Therapy: Oncolytics. 3: 16011. doi:10.1038/mto.2016.11. PMC 5008265. PMID 27626062.
Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B (June 2021). "CAR-T cell therapy and infection: a review". Expert Review of Anti-Infective Therapy. 19 (6): 749–758. doi:10.1080/14787210.2021.1855143. PMID 33249873. S2CID 227235627.
Breslin S (February 2007). "Cytokine-release syndrome: overview and nursing implications". Clinical Journal of Oncology Nursing. 11 (1 Suppl): 37–42. doi:10.1188/07.CJON.S1.37-42. PMID 17471824. S2CID 35773028.
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. (July 2014). "Current concepts in the diagnosis and management of cytokine release syndrome". Blood. 124 (2): 188–195. doi:10.1182/blood-2014-05-552729. PMC 4093680. PMID 24876563.
Berg P, Schönefeld S, Ruppert-Seipp G, Funk MB (2022-11-29). "Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment". Transfusion Medicine and Hemotherapy. 50 (3): 218–225. doi:10.1159/000526786. ISSN 1660-3796. PMC 10331154. PMID 37435000.
Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, et al. (December 2019). "Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy". Blood. 134 (24): 2149–2158. doi:10.1182/blood.2019001463. PMC 6908832. PMID 31697826.
Tan AH, Vinanica N, Campana D (April 2020). "Chimeric antigen receptor-T cells with cytokine neutralizing capacity". Blood advances. 4 (7): 1419–1431. doi:10.1182/bloodadvances.2019001287. PMC 7160280. PMID 32271901.
Brudno JN, Kochenderfer JN (June 2016). "Toxicities of chimeric antigen receptor T cells: recognition and management". Blood. 127 (26): 3321–3330. doi:10.1182/blood-2016-04-703751. PMC 4929924. PMID 27207799.
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. (June 2016). "CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients". The Journal of Clinical Investigation. 126 (6): 2123–2138. doi:10.1172/JCI85309. PMC 4887159. PMID 27111235.
Gust, Juliane (October 5, 2023). "BCMA-CAR T-cell treatment–associated parkinsonism". Blood. 142 (14): 1181–1183. doi:10.1182/blood.2023021860. PMID 37796518. Retrieved April 4, 2024.
Chandran SS, Klebanoff CA (July 2019). "T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance". Immunological Reviews. 290 (1): 127–147. doi:10.1111/imr.12772. PMC 7027847. PMID 31355495. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Dotti G, Gottschalk S, Savoldo B, Brenner MK (January 2014). "Design and development of therapies using chimeric antigen receptor-expressing T cells". Immunological Reviews. 257 (1): 107–126. doi:10.1111/imr.12131. PMC 3874724. PMID 24329793.
Zhang C, Liu J, Zhong JF, Zhang X (2017-06-24). "Engineering CAR-T cells". Biomarker Research. 5: 22. doi:10.1186/s40364-017-0102-y. PMC 5482931. PMID 28652918.
Baldo BA (May 2015). "Chimeric fusion proteins used for therapy: indications, mechanisms, and safety". Drug Safety. 38 (5): 455–479. doi:10.1007/s40264-015-0285-9. PMID 25832756. S2CID 23852865.
Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M (August 2017). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America. 114 (32): E6623–E6631. Bibcode:2017PNAS..114E6623L. doi:10.1073/pnas.1706055114. PMC 5559039. PMID 28739923.
Li, Nan; Quan, Alex; Li, Dan; Pan, Jiajia; Ren, Hua; Hoeltzel, Gerard; de Val, Natalia; Ashworth, Dana; Ni, Weiming; Zhou, Jing; Mackay, Sean; Hewitt, Stephen M.; Cachau, Raul; Ho, Mitchell (2023-04-08). "The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer". Nature Communications. 14 (1): 1986. Bibcode:2023NatCo..14.1986L. doi:10.1038/s41467-023-37616-4. ISSN 2041-1723. PMC 10082787. PMID 37031249.
Kolluri, Aarti; Li, Dan; Li, Nan; Duan, Zhijian; Roberts, Lewis R.; Ho, Mitchell (2023-02-01). "Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC". Hepatology Communications. 7 (2): e0022. doi:10.1097/HC9.0000000000000022. ISSN 2471-254X. PMC 9851680. PMID 36691969.
Li, Dan; English, Hejiao; Hong, Jessica; Liang, Tianyuzhou; Merlino, Glenn; Day, Chi-Ping; Ho, Mitchell (2022-03-17). "A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer". Molecular Therapy: Oncolytics. 24: 849–863. doi:10.1016/j.omto.2022.02.015. ISSN 2372-7705. PMC 8917269. PMID 35317524.
Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. (February 2015). "The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity". Cancer Immunology Research. 3 (2): 125–135. doi:10.1158/2326-6066.CIR-14-0127. PMC 4692801. PMID 25212991.
Qin L, Lai Y, Zhao R, Wei X, Weng J, Lai P, et al. (March 2017). "Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells". Journal of Hematology & Oncology. 10 (1): 68. doi:10.1186/s13045-017-0437-8. PMC 5347831. PMID 28288656.
Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE (June 2010). "The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex". Journal of Immunology. 184 (12): 6938–6949. doi:10.4049/jimmunol.0901766. PMID 20483753.
Casucci M, Bondanza A (2011). "Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes". Journal of Cancer. 2: 378–382. doi:10.7150/jca.2.378. PMC 3133962. PMID 21750689.
Choe JH, Williams JZ, Lim WA (2020). "Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology". Annual Review of Cancer Biology. 4: 121–139. doi:10.1146/annurev-cancerbio-030419-033657.
Cho JH, Collins JJ, Wong WW (May 2018). "Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses". Cell. 173 (6): 1426–1438.e11. doi:10.1016/j.cell.2018.03.038. PMC 5984158. PMID 29706540.
Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE (March 2018). "CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity". Molecular Therapy: Oncolytics. 8: 41–51. doi:10.1016/j.omto.2017.12.003. PMC 5772011. PMID 29367945.
Chmielewski M, Abken H (2015). "TRUCKs: the fourth generation of CARs". Expert Opinion on Biological Therapy. 15 (8): 1145–1154. doi:10.1517/14712598.2015.1046430. PMID 25985798. S2CID 42535203.
Zhang E, Xu H (January 2017). "A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy". Journal of Hematology & Oncology. 10 (1): 1. doi:10.1186/s13045-016-0379-6. PMC 5210295. PMID 28049484.
Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. (June 1997). "HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia". Science. 276 (5319): 1719–1724. doi:10.1126/science.276.5319.1719. PMID 9180086.
Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, et al. (October 2007). "Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes". Blood. 110 (8): 2793–2802. doi:10.1182/blood-2007-02-072843. PMC 2018664. PMID 17638856.
Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, et al. (February 1996). "T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients". Nature Medicine. 2 (2): 216–223. doi:10.1038/nm0296-216. PMID 8574968. S2CID 35503876.
Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M (January 2002). "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor". Nature Biotechnology. 20 (1): 70–75. doi:10.1038/nbt0102-70. PMID 11753365. S2CID 20302096.
Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. (October 2012). "Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling". Journal of Clinical Immunology. 32 (5): 1059–1070. doi:10.1007/s10875-012-9689-9. PMID 22526592. S2CID 17660404.
Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA (October 2015). "Remote control of therapeutic T cells through a small molecule-gated chimeric receptor". Science. 350 (6258): aab4077. Bibcode:2015Sci...350.4077W. doi:10.1126/science.aab4077. PMC 4721629. PMID 26405231.
Frankel SR, Baeuerle PA (June 2013). "Targeting T cells to tumor cells using bispecific antibodies". Current Opinion in Chemical Biology. 17 (3): 385–392. doi:10.1016/j.cbpa.2013.03.029. PMID 23623807.
Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, et al. (May 2015). "Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies". Science Translational Medicine. 7 (287): 287ra70. doi:10.1126/scitranslmed.aaa4802. PMID 25972002. S2CID 24939667.
Kim CH, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, et al. (October 2013). "Bispecific small molecule-antibody conjugate targeting prostate cancer". Proceedings of the National Academy of Sciences of the United States of America. 110 (44): 17796–17801. Bibcode:2013PNAS..11017796K. doi:10.1073/pnas.1316026110. PMC 3816437. PMID 24127589.
Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC (April 2020). "Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma". JAMA Network Open. 3 (4): e202072. doi:10.1001/jamanetworkopen.2020.2072. PMC 7136832. PMID 32250433.
Smith, Tyrel T.; Stephan, Sirkka B.; Moffett, Howell F.; McKnight, Laura E.; Ji, Weihang; Reiman, Diana; Bonagofski, Emmy; Wohlfahrt, Martin E.; Pillai, Smitha P. S.; Stephan, Matthias T. (2017-04-17). "In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers". Nature Nanotechnology. 12 (8): 813–820. doi:10.1038/nnano.2017.57. ISSN 1748-3387. PMC 5646367. PMID 28416815.
Agarwal, Shiwani; Weidner, Tatjana; Thalheimer, Frederic B.; Buchholz, Christian J. (2019-10-10). "In vivo generated human CAR T cells eradicate tumor cells". OncoImmunology. 8 (12): e1671761. doi:10.1080/2162402x.2019.1671761. ISSN 2162-402X. PMC 6844313. PMID 31741773.
Agarwalla, Pritha; Ogunnaike, Edikan A.; Ahn, Sarah; Froehlich, Kristen A.; Jansson, Anton; Ligler, Frances S.; Dotti, Gianpietro; Brudno, Yevgeny (2022-03-24). "Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells". Nature Biotechnology. 40 (8): 1250–1258. doi:10.1038/s41587-022-01245-x. ISSN 1087-0156. PMC 9376243. PMID 35332339.
Ghassemi, Saba; Durgin, Joseph S.; Nunez-Cruz, Selene; Patel, Jai; Leferovich, John; Pinzone, Marilia; Shen, Feng; Cummins, Katherine D.; Plesa, Gabriela; Cantu, Vito Adrian; Reddy, Shantan; Bushman, Frederic D.; Gill, Saar I.; O'Doherty, Una; O'Connor, Roddy S. (February 2022). "Rapid manufacturing of non-activated potent CAR T cells". Nature Biomedical Engineering. 6 (2): 118–128. doi:10.1038/s41551-021-00842-6. ISSN 2157-846X. PMC 8860360. PMID 35190680.
Ledford, Heidi (2023-12-20). "Cancer-fighting CAR-T cells could be made inside body with viral injection". Nature. 625 (7994): 225–226. doi:10.1038/d41586-023-03969-5. PMID 38129613.
Chakraborty, Samik; Ye, Juan; Wang, Herui; Sun, Mitchell; Zhang, Yaping; Sang, Xueyu; Zhuang, Zhengping (2023-10-23). "Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy". Frontiers in Immunology. 14. doi:10.3389/fimmu.2023.1227833. ISSN 1664-3224. PMC 10626551. PMID 37936697.
Mikolič, Veronika; Pantović-Žalig, Jelica; Malenšek, Špela; Sever, Matjaž; Lainšček, Duško; Jerala, Roman (June 2024). "Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors". Molecular Therapy: Oncology. 32 (2): 200815. doi:10.1016/j.omton.2024.200815. ISSN 2950-3299. PMC 11152746. PMID 38840781.
Chen, Xue; Zhang, Yunxiao; Fu, Yao (2022-06-01). "The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy". Medicine in Drug Discovery. 14: 100122. doi:10.1016/j.medidd.2022.100122. ISSN 2590-0986.
Wu, Ling; Brzostek, Joanna; Sakthi Vale, Previtha Dawn; Wei, Qianru; Koh, Clara K. T.; Ong, June Xu Hui; Wu, Liang-Zhe; Tan, Jia Chi; Chua, Yen Leong; Yap, Jiawei; Song, Yuan; Tan, Vivian Jia Yi; Tan, Triscilla Y. Y.; Lai, Junyun; MacAry, Paul A. (2023-02-21). "CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance". Cell Reports. Medicine. 4 (2): 100917. doi:10.1016/j.xcrm.2023.100917. ISSN 2666-3791. PMC 9975250. PMID 36696897.
Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi; Bhoj, Vijay; Gershenson, Zack; Moon, Edmund; Newick, Kheng; Sun, Jing; Lo, Albert; Baradet, Timothy; Feldman, Michael D.; Barrett, David; Puré, Ellen; Albelda, Steven; Milone, Michael C. (July 2015). "Generation of Potent T-cell Immunotherapy for Cancer using DAP12-based, Multichain, Chimeric Immunoreceptors". Cancer Immunology Research. 3 (7): 815–826. doi:10.1158/2326-6066.CIR-15-0054. ISSN 2326-6066. PMC 4490943. PMID 25941351.
"152. A Chimeric Antigen Receptor (CARs) Based Upon a Killer Immunoglobulin-Like Receptor (KIR) Triggers Robust Cytotoxic Activity in Solid Tumors". Molecular Therapy. 22: S57. May 2014. doi:10.1016/s1525-0016(16)35165-6. ISSN 1525-0016.
Xu, Jun; Nunez-Cruz, Selene; Leferovich, John M.; Gulendran, Gayathri; Zhang, Chune; Yucel, Nora D.; Blair, Megan C.; Stanley, William S.; Johnson, Laura A.; Siegel, Don L.; Milone, Michael C. (2024-03-22). "Abstract 6332: Evaluating the relationship of affinity, functional avidity, and in vivo potency in KIR-CAR T cells". Cancer Research. 84 (6_Supplement): 6332. doi:10.1158/1538-7445.AM2024-6332. ISSN 1538-7445.
Prinzing, Brooke; Schreiner, Patrick; Bell, Matthew; Fan, Yiping; Krenciute, Giedre; Gottschalk, Stephen (2020-11-05). "MyD88/CD40 signaling retains CAR T cells in a less differentiated state". JCI Insight. 5 (21): e136093, 136093. doi:10.1172/jci.insight.136093. ISSN 2379-3708. PMC 7710311. PMID 33148882.
Collinson-Pautz, Matthew R.; Chang, Wei-Chun; Lu, An; Khalil, Mariam; Crisostomo, Jeannette W.; Lin, Pei-Yi; Mahendravada, Aruna; Shinners, Nicholas P.; Brandt, Mary E.; Zhang, Ming; Duong, MyLinh; Bayle, J. Henri; Slawin, Kevin M.; Spencer, David M.; Foster, Aaron E. (September 2019). "Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies". Leukemia. 33 (9): 2195–2207. doi:10.1038/s41375-019-0417-9. ISSN 1476-5551. PMC 6756044. PMID 30816327.
Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA (September 2020). "Value and affordability of CAR T-cell therapy in the United States". Bone Marrow Transplantation. 55 (9): 1706–1715. doi:10.1038/s41409-020-0956-8. PMID 32474570. S2CID 218987876.

dx.doi.org

Smith, Tyrel T.; Stephan, Sirkka B.; Moffett, Howell F.; McKnight, Laura E.; Ji, Weihang; Reiman, Diana; Bonagofski, Emmy; Wohlfahrt, Martin E.; Pillai, Smitha P. S.; Stephan, Matthias T. (2017-04-17). "In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers". Nature Nanotechnology. 12 (8): 813–820. doi:10.1038/nnano.2017.57. ISSN 1748-3387. PMC 5646367. PMID 28416815.
Agarwal, Shiwani; Weidner, Tatjana; Thalheimer, Frederic B.; Buchholz, Christian J. (2019-10-10). "In vivo generated human CAR T cells eradicate tumor cells". OncoImmunology. 8 (12): e1671761. doi:10.1080/2162402x.2019.1671761. ISSN 2162-402X. PMC 6844313. PMID 31741773.
Agarwalla, Pritha; Ogunnaike, Edikan A.; Ahn, Sarah; Froehlich, Kristen A.; Jansson, Anton; Ligler, Frances S.; Dotti, Gianpietro; Brudno, Yevgeny (2022-03-24). "Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells". Nature Biotechnology. 40 (8): 1250–1258. doi:10.1038/s41587-022-01245-x. ISSN 1087-0156. PMC 9376243. PMID 35332339.

endocyte.com

SMDC technology. Archived 2016-03-27 at the Wayback Machine ENDOCYTE

investor.endocyte.com

"Endocyte announces promising preclinical data for application of SMDC technology in CAR T cell therapy in late-breaking abstract at American Association for Cancer Research (AACR) annual meeting 2016" (Press release). Endocyte. April 19, 2016. Archived from the original on July 30, 2017. Retrieved December 20, 2017.

europa.eu

ema.europa.eu

European Medicines Agency (2023-01-30). "TECARTUS (brexucabtagene autoleucel)". EMA.
European Medicines Agency (2023-11-10). "Breyanzi". EMA.
European Medicines Agency (2023-07-27). "Abecma". EMA.
European Medicines Agency (2023-07-27). "Carvykti". EMA.

fda.gov

Center for Biologics Evaluation and Research (2022-03-01). "Approved Cellular and Gene Therapy Products". FDA.
"KYMRIAH (tisagenlecleucel)". US Food and Drug Administration. 2019-04-05.
Center for Biologics Evaluation and Research (2017-10-18). "FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma". FDA.
Center for Biologics Evaluation and Research (2020-05-28). "YESCARTA (axicabtagene ciloleucel)". FDA.
Center for Biologics Evaluation and Research (2021-03-04). "TECARTUS (brexucabtagene autoleucel)". FDA.
Center for Biologics Evaluation and Research (2021-03-04). "TECARTUS (brexucabtagene autoleucel)". FDA.
Center for Biologics Evaluation and Research (2022-06-24). "FDA D.I.S.C.O. Burst Edition: FDA approval of Breyanzi (lisocabtagene maraleucel) for second-line treatment of large B-cell lymphoma". FDA.
Center for Biologics Evaluation and Research (2021-03-27). "ABECMA (idecabtagene vicleucel)". FDA.
Center for Biologics Evaluation and Research (2022-03-21). "CARVYKTI". FDA.
Research, Center for Drug Evaluation and (2024-11-08). "FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia". FDA.

gilead.com

"Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy". www.gilead.com. Retrieved 2023-11-18.
"Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China". www.gilead.com. Retrieved 2023-11-13.
"Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma". www.gilead.com. 2022-12-22.
"Kite's CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma". www.gilead.com. Retrieved 2023-11-18.
"U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy". www.gilead.com. Retrieved 2021-03-15.
"Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma". www.gilead.com. Retrieved 2023-11-18.

gov.br

"Anvisa aprova produto de terapia avançada para tratamento de câncer". Agência Nacional de Vigilância Sanitária - Anvisa (in Brazilian Portuguese). 2022-02-23. Retrieved 2022-06-07.

harvard.edu

ui.adsabs.harvard.edu

Gross G, Waks T, Eshhar Z (December 1989). "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity". Proceedings of the National Academy of Sciences of the United States of America. 86 (24): 10024–10028. Bibcode:1989PNAS...8610024G. doi:10.1073/pnas.86.24.10024. JSTOR 34790. PMC 298636. PMID 2513569.
Li, Nan; Fu, Haiying; Hewitt, Stephen M.; Dimitrov, Dimiter S.; Ho, Mitchell (2017-08-08). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America. 114 (32): E6623–E6631. Bibcode:2017PNAS..114E6623L. doi:10.1073/pnas.1706055114. ISSN 1091-6490. PMC 5559039. PMID 28739923.
Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M (August 2017). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America. 114 (32): E6623–E6631. Bibcode:2017PNAS..114E6623L. doi:10.1073/pnas.1706055114. PMC 5559039. PMID 28739923.
Li, Nan; Quan, Alex; Li, Dan; Pan, Jiajia; Ren, Hua; Hoeltzel, Gerard; de Val, Natalia; Ashworth, Dana; Ni, Weiming; Zhou, Jing; Mackay, Sean; Hewitt, Stephen M.; Cachau, Raul; Ho, Mitchell (2023-04-08). "The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer". Nature Communications. 14 (1): 1986. Bibcode:2023NatCo..14.1986L. doi:10.1038/s41467-023-37616-4. ISSN 2041-1723. PMC 10082787. PMID 37031249.
Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA (October 2015). "Remote control of therapeutic T cells through a small molecule-gated chimeric receptor". Science. 350 (6258): aab4077. Bibcode:2015Sci...350.4077W. doi:10.1126/science.aab4077. PMC 4721629. PMID 26405231.
Kim CH, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, et al. (October 2013). "Bispecific small molecule-antibody conjugate targeting prostate cancer". Proceedings of the National Academy of Sciences of the United States of America. 110 (44): 17796–17801. Bibcode:2013PNAS..11017796K. doi:10.1073/pnas.1316026110. PMC 3816437. PMID 24127589.

hematology.org

"CAR T-cell Therapy: An Update on Coverage and Reimbursement - Hematology.org". www.hematology.org. Archived from the original on 2022-01-24. Retrieved 2021-03-22.

jstor.org

Gross G, Waks T, Eshhar Z (December 1989). "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity". Proceedings of the National Academy of Sciences of the United States of America. 86 (24): 10024–10028. Bibcode:1989PNAS...8610024G. doi:10.1073/pnas.86.24.10024. JSTOR 34790. PMC 298636. PMID 2513569.

labiotech.eu

"A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology" (Press release). labiotech. March 8, 2018. Retrieved April 19, 2018.

nature.com

Ledford, Heidi (2023-12-20). "Cancer-fighting CAR-T cells could be made inside body with viral injection". Nature. 625 (7994): 225–226. doi:10.1038/d41586-023-03969-5. PMID 38129613.

nbcnews.com

Fox M (July 12, 2017). "New Gene Therapy for Cancer Offers Hope to Those With No Options Left". NBC News.

nejm.org

Choi, Bryan D.; Gerstner, Elizabeth R.; Frigault, Matthew J.; Leick, Mark B.; Mount, Christopher W.; Balaj, Leonora; Nikiforow, Sarah; Carter, Bob S.; Curry, William T.; Gallagher, Kathleen; Maus, Marcela V. (2024-04-11). "Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma". New England Journal of Medicine. 390 (14): 1290–1298. doi:10.1056/NEJMoa2314390. ISSN 0028-4793. PMC 11162836. PMID 38477966.

nih.gov

pubmed.ncbi.nlm.nih.gov

Srivastava S, Riddell SR (August 2015). "Engineering CAR-T cells: Design concepts". Trends in Immunology. 36 (8): 494–502. doi:10.1016/j.it.2015.06.004. PMC 4746114. PMID 26169254.
Sadelain M, Brentjens R, Rivière I (April 2013). "The basic principles of chimeric antigen receptor design". Cancer Discovery. 3 (4): 388–398. doi:10.1158/2159-8290.CD-12-0548. PMC 3667586. PMID 23550147.
Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ (September 2017). "Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts". EMBO Molecular Medicine. 9 (9): 1183–1197. doi:10.15252/emmm.201607485. PMC 5582407. PMID 28765140.
Tang XJ, Sun XY, Huang KM, Zhang L, Yang ZS, Zou DD, et al. (December 2015). "Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy". Oncotarget. 6 (42): 44179–44190. doi:10.18632/oncotarget.6175. PMC 4792550. PMID 26496034.
Zhang H, Zhao P, Huang H (December 2020). "Engineering better chimeric antigen receptor T cells". Experimental Hematology & Oncology. 9 (1): 34. doi:10.1186/s40164-020-00190-2. PMC 7709221. PMID 33292660.
Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. (December 1987). "Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions". Biochemical and Biophysical Research Communications. 149 (3): 960–968. doi:10.1016/0006-291x(87)90502-x. PMID 3122749.
Gross G, Gorochov G, Waks T, Eshhar Z (February 1989). "Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity". Transplantation Proceedings. 21 (1 Pt 1): 127–130. PMID 2784887.
Rosenbaum L (October 2017). "Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy". The New England Journal of Medicine. 377 (14): 1313–1315. doi:10.1056/NEJMp1711886. PMID 28902570. S2CID 205114161.
Gross G, Waks T, Eshhar Z (December 1989). "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity". Proceedings of the National Academy of Sciences of the United States of America. 86 (24): 10024–10028. Bibcode:1989PNAS...8610024G. doi:10.1073/pnas.86.24.10024. JSTOR 34790. PMC 298636. PMID 2513569.
Eshhar Z, Bach N, Fitzer-Attas CJ, Gross G, Lustgarten J, Waks T, Schindler DG (1996). "The T-body approach: potential for cancer immunotherapy". Springer Seminars in Immunopathology. 18 (2): 199–209. doi:10.1007/BF00820666. PMID 8908700. S2CID 19872173.
Irving BA, Weiss A (March 1991). "The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways". Cell. 64 (5): 891–901. doi:10.1016/0092-8674(91)90314-o. PMID 1705867. S2CID 23466990.
Hege KM, Roberts MR (December 1996). "T-cell gene therapy". Current Opinion in Biotechnology. 7 (6): 629–634. doi:10.1016/s0958-1669(96)80074-7. PMID 8939644.
June CH, Sadelain M (July 2018). "Chimeric Antigen Receptor Therapy". The New England Journal of Medicine. 379 (1): 64–73. doi:10.1056/NEJMra1706169. PMC 7433347. PMID 29972754.
Braendstrup P, Levine BL, Ruella M (February 2020). "The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19". Cytotherapy. 22 (2): 57–69. doi:10.1016/j.jcyt.2019.12.004. PMC 7036015. PMID 32014447.
Sadelain M, Rivière I, Brentjens R (January 2003). "Targeting tumours with genetically enhanced T lymphocytes". Nature Reviews. Cancer. 3 (1): 35–45. doi:10.1038/nrc971. PMID 12509765. S2CID 33707802.
Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M (2014-03-05). "Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors". Molecular Therapy: Methods & Clinical Development. 1: 14001. doi:10.1038/mtm.2014.1. PMC 4362340. PMID 26015949.
Li, Nan; Ho, Mitchell (2022). "Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma". Single-Domain Antibodies. Methods in Molecular Biology. Vol. 2446. pp. 451–468. doi:10.1007/978-1-0716-2075-5_23. ISBN 978-1-0716-2074-8. ISSN 1940-6029. PMID 35157288. S2CID 246813053.
Makita S, Yoshimura K, Tobinai K (June 2017). "Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma". Cancer Science. 108 (6): 1109–1118. doi:10.1111/cas.13239. PMC 5480083. PMID 28301076.
Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D (July 2016). "Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer". EMBO Molecular Medicine. 8 (7): 702–711. doi:10.15252/emmm.201505869. PMC 4931286. PMID 27189167.
Jensen TI, Axelgaard E, Bak RO (June 2019). "Therapeutic gene editing in haematological disorders with CRISPR/Cas9". British Journal of Haematology. 185 (5): 821–835. doi:10.1111/bjh.15851. PMID 30864164.
Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP (December 2006). "Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?". Nature Clinical Practice. Oncology. 3 (12): 668–681. doi:10.1038/ncponc0666. PMC 1773008. PMID 17139318.
Xin Yu J, Hubbard-Lucey VM, Tang J (October 2019). "The global pipeline of cell therapies for cancer". Nature Reviews. Drug Discovery. 18 (11): 821–822. doi:10.1038/d41573-019-00090-z. PMID 31673124. S2CID 190862546.
Almåsbak H, Aarvak T, Vemuri MC (2016). "CAR T Cell Therapy: A Game Changer in Cancer Treatment". Journal of Immunology Research. 2016: 5474602. doi:10.1155/2016/5474602. PMC 4889848. PMID 27298832.
Jacobson CA, Ritz J (November 2011). "Time to put the CAR-T before the horse". Blood. 118 (18): 4761–4762. doi:10.1182/blood-2011-09-376137. PMID 22053170.
Li, Nan; Spetz, Madeline R.; Li, Dan; Ho, Mitchell (July 2021). "Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3". Pharmacology & Therapeutics. 223: 107892. doi:10.1016/j.pharmthera.2021.107892. ISSN 1879-016X. PMC 8202769. PMID 33992682.
Li, Dan; Lin, Shaoli; Hong, Jessica; Ho, Mitchell (2022). "Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances". Advances in Cancer Research. 156: 415–449. doi:10.1016/bs.acr.2022.01.013. ISBN 9780323983921. ISSN 2162-5557. PMID 35961708. S2CID 246978004.
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. (November 2010). "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19". Blood. 116 (20): 4099–4102. doi:10.1182/blood-2010-04-281931. PMC 2993617. PMID 20668228.
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. (February 2015). "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor". Journal of Clinical Oncology. 33 (6): 540–549. doi:10.1200/JCO.2014.56.2025. PMC 4322257. PMID 25154820.
Schultz L, Mackall C (February 2019). "Driving CAR T cell translation forward". Science Translational Medicine. 11 (481): eaaw2127. doi:10.1126/scitranslmed.aaw2127. PMID 30814337.
Choi, Bryan D.; Gerstner, Elizabeth R.; Frigault, Matthew J.; Leick, Mark B.; Mount, Christopher W.; Balaj, Leonora; Nikiforow, Sarah; Carter, Bob S.; Curry, William T.; Gallagher, Kathleen; Maus, Marcela V. (2024-04-11). "Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma". New England Journal of Medicine. 390 (14): 1290–1298. doi:10.1056/NEJMoa2314390. ISSN 0028-4793. PMC 11162836. PMID 38477966.
Lim WA, June CH (February 2017). "The Principles of Engineering Immune Cells to Treat Cancer". Cell. 168 (4): 724–740. doi:10.1016/j.cell.2017.01.016. PMC 5553442. PMID 28187291.
Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, et al. (June 2020). "Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice". Gastroenterology. 158 (8): 2250–2265.e20. doi:10.1053/j.gastro.2020.02.011. PMC 7282931. PMID 32060001.
Li, Nan; Fu, Haiying; Hewitt, Stephen M.; Dimitrov, Dimiter S.; Ho, Mitchell (2017-08-08). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America. 114 (32): E6623–E6631. Bibcode:2017PNAS..114E6623L. doi:10.1073/pnas.1706055114. ISSN 1091-6490. PMC 5559039. PMID 28739923.
Li, Nan; Torres, Madeline B.; Spetz, Madeline R.; Wang, Ruixue; Peng, Luyi; Tian, Meijie; Dower, Christopher M.; Nguyen, Rosa; Sun, Ming; Tai, Chin-Hsien; de Val, Natalia; Cachau, Raul; Wu, Xiaolin; Hewitt, Stephen M.; Kaplan, Rosandra N. (2021-06-15). "CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice". Cell Reports. Medicine. 2 (6): 100297. doi:10.1016/j.xcrm.2021.100297. ISSN 2666-3791. PMC 8233664. PMID 34195677.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M (May 2008). "Regulatory T cells and immune tolerance". Cell. 133 (5): 775–787. doi:10.1016/j.cell.2008.05.009. PMID 18510923. S2CID 2315895.
Zhang Q, Lu W, Liang CL, Chen Y, Liu H, Qiu F, Dai Z (2018). "Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance". Frontiers in Immunology. 9: 2359. doi:10.3389/fimmu.2018.02359. PMC 6194362. PMID 30369931.
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. (August 2021). "CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus". The New England Journal of Medicine. 385 (6): 567–569. doi:10.1056/NEJMc2107725. PMID 34347960. S2CID 236927691.
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016). "Toxicity and management in CAR T-cell therapy". Molecular Therapy: Oncolytics. 3: 16011. doi:10.1038/mto.2016.11. PMC 5008265. PMID 27626062.
Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B (June 2021). "CAR-T cell therapy and infection: a review". Expert Review of Anti-Infective Therapy. 19 (6): 749–758. doi:10.1080/14787210.2021.1855143. PMID 33249873. S2CID 227235627.
Breslin S (February 2007). "Cytokine-release syndrome: overview and nursing implications". Clinical Journal of Oncology Nursing. 11 (1 Suppl): 37–42. doi:10.1188/07.CJON.S1.37-42. PMID 17471824. S2CID 35773028.
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. (July 2014). "Current concepts in the diagnosis and management of cytokine release syndrome". Blood. 124 (2): 188–195. doi:10.1182/blood-2014-05-552729. PMC 4093680. PMID 24876563.
Berg P, Schönefeld S, Ruppert-Seipp G, Funk MB (2022-11-29). "Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment". Transfusion Medicine and Hemotherapy. 50 (3): 218–225. doi:10.1159/000526786. ISSN 1660-3796. PMC 10331154. PMID 37435000.
Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, et al. (December 2019). "Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy". Blood. 134 (24): 2149–2158. doi:10.1182/blood.2019001463. PMC 6908832. PMID 31697826.
Tan AH, Vinanica N, Campana D (April 2020). "Chimeric antigen receptor-T cells with cytokine neutralizing capacity". Blood advances. 4 (7): 1419–1431. doi:10.1182/bloodadvances.2019001287. PMC 7160280. PMID 32271901.
Brudno JN, Kochenderfer JN (June 2016). "Toxicities of chimeric antigen receptor T cells: recognition and management". Blood. 127 (26): 3321–3330. doi:10.1182/blood-2016-04-703751. PMC 4929924. PMID 27207799.
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. (June 2016). "CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients". The Journal of Clinical Investigation. 126 (6): 2123–2138. doi:10.1172/JCI85309. PMC 4887159. PMID 27111235.
Gust, Juliane (October 5, 2023). "BCMA-CAR T-cell treatment–associated parkinsonism". Blood. 142 (14): 1181–1183. doi:10.1182/blood.2023021860. PMID 37796518. Retrieved April 4, 2024.
Chandran SS, Klebanoff CA (July 2019). "T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance". Immunological Reviews. 290 (1): 127–147. doi:10.1111/imr.12772. PMC 7027847. PMID 31355495. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Dotti G, Gottschalk S, Savoldo B, Brenner MK (January 2014). "Design and development of therapies using chimeric antigen receptor-expressing T cells". Immunological Reviews. 257 (1): 107–126. doi:10.1111/imr.12131. PMC 3874724. PMID 24329793.
Zhang C, Liu J, Zhong JF, Zhang X (2017-06-24). "Engineering CAR-T cells". Biomarker Research. 5: 22. doi:10.1186/s40364-017-0102-y. PMC 5482931. PMID 28652918.
Baldo BA (May 2015). "Chimeric fusion proteins used for therapy: indications, mechanisms, and safety". Drug Safety. 38 (5): 455–479. doi:10.1007/s40264-015-0285-9. PMID 25832756. S2CID 23852865.
Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M (August 2017). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America. 114 (32): E6623–E6631. Bibcode:2017PNAS..114E6623L. doi:10.1073/pnas.1706055114. PMC 5559039. PMID 28739923.
Li, Nan; Quan, Alex; Li, Dan; Pan, Jiajia; Ren, Hua; Hoeltzel, Gerard; de Val, Natalia; Ashworth, Dana; Ni, Weiming; Zhou, Jing; Mackay, Sean; Hewitt, Stephen M.; Cachau, Raul; Ho, Mitchell (2023-04-08). "The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer". Nature Communications. 14 (1): 1986. Bibcode:2023NatCo..14.1986L. doi:10.1038/s41467-023-37616-4. ISSN 2041-1723. PMC 10082787. PMID 37031249.
Kolluri, Aarti; Li, Dan; Li, Nan; Duan, Zhijian; Roberts, Lewis R.; Ho, Mitchell (2023-02-01). "Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC". Hepatology Communications. 7 (2): e0022. doi:10.1097/HC9.0000000000000022. ISSN 2471-254X. PMC 9851680. PMID 36691969.
Li, Dan; English, Hejiao; Hong, Jessica; Liang, Tianyuzhou; Merlino, Glenn; Day, Chi-Ping; Ho, Mitchell (2022-03-17). "A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer". Molecular Therapy: Oncolytics. 24: 849–863. doi:10.1016/j.omto.2022.02.015. ISSN 2372-7705. PMC 8917269. PMID 35317524.
Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. (February 2015). "The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity". Cancer Immunology Research. 3 (2): 125–135. doi:10.1158/2326-6066.CIR-14-0127. PMC 4692801. PMID 25212991.
Qin L, Lai Y, Zhao R, Wei X, Weng J, Lai P, et al. (March 2017). "Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells". Journal of Hematology & Oncology. 10 (1): 68. doi:10.1186/s13045-017-0437-8. PMC 5347831. PMID 28288656.
Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE (June 2010). "The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex". Journal of Immunology. 184 (12): 6938–6949. doi:10.4049/jimmunol.0901766. PMID 20483753.
Casucci M, Bondanza A (2011). "Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes". Journal of Cancer. 2: 378–382. doi:10.7150/jca.2.378. PMC 3133962. PMID 21750689.
Cho JH, Collins JJ, Wong WW (May 2018). "Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses". Cell. 173 (6): 1426–1438.e11. doi:10.1016/j.cell.2018.03.038. PMC 5984158. PMID 29706540.
Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE (March 2018). "CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity". Molecular Therapy: Oncolytics. 8: 41–51. doi:10.1016/j.omto.2017.12.003. PMC 5772011. PMID 29367945.
Chmielewski M, Abken H (2015). "TRUCKs: the fourth generation of CARs". Expert Opinion on Biological Therapy. 15 (8): 1145–1154. doi:10.1517/14712598.2015.1046430. PMID 25985798. S2CID 42535203.
Zhang E, Xu H (January 2017). "A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy". Journal of Hematology & Oncology. 10 (1): 1. doi:10.1186/s13045-016-0379-6. PMC 5210295. PMID 28049484.
Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. (June 1997). "HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia". Science. 276 (5319): 1719–1724. doi:10.1126/science.276.5319.1719. PMID 9180086.
Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, et al. (October 2007). "Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes". Blood. 110 (8): 2793–2802. doi:10.1182/blood-2007-02-072843. PMC 2018664. PMID 17638856.
Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, et al. (February 1996). "T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients". Nature Medicine. 2 (2): 216–223. doi:10.1038/nm0296-216. PMID 8574968. S2CID 35503876.
Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M (January 2002). "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor". Nature Biotechnology. 20 (1): 70–75. doi:10.1038/nbt0102-70. PMID 11753365. S2CID 20302096.
Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. (October 2012). "Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling". Journal of Clinical Immunology. 32 (5): 1059–1070. doi:10.1007/s10875-012-9689-9. PMID 22526592. S2CID 17660404.
Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA (October 2015). "Remote control of therapeutic T cells through a small molecule-gated chimeric receptor". Science. 350 (6258): aab4077. Bibcode:2015Sci...350.4077W. doi:10.1126/science.aab4077. PMC 4721629. PMID 26405231.
Frankel SR, Baeuerle PA (June 2013). "Targeting T cells to tumor cells using bispecific antibodies". Current Opinion in Chemical Biology. 17 (3): 385–392. doi:10.1016/j.cbpa.2013.03.029. PMID 23623807.
Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, et al. (May 2015). "Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies". Science Translational Medicine. 7 (287): 287ra70. doi:10.1126/scitranslmed.aaa4802. PMID 25972002. S2CID 24939667.
Kim CH, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, et al. (October 2013). "Bispecific small molecule-antibody conjugate targeting prostate cancer". Proceedings of the National Academy of Sciences of the United States of America. 110 (44): 17796–17801. Bibcode:2013PNAS..11017796K. doi:10.1073/pnas.1316026110. PMC 3816437. PMID 24127589.
Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC (April 2020). "Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma". JAMA Network Open. 3 (4): e202072. doi:10.1001/jamanetworkopen.2020.2072. PMC 7136832. PMID 32250433.
Smith, Tyrel T.; Stephan, Sirkka B.; Moffett, Howell F.; McKnight, Laura E.; Ji, Weihang; Reiman, Diana; Bonagofski, Emmy; Wohlfahrt, Martin E.; Pillai, Smitha P. S.; Stephan, Matthias T. (2017-04-17). "In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers". Nature Nanotechnology. 12 (8): 813–820. doi:10.1038/nnano.2017.57. ISSN 1748-3387. PMC 5646367. PMID 28416815.
Agarwal, Shiwani; Weidner, Tatjana; Thalheimer, Frederic B.; Buchholz, Christian J. (2019-10-10). "In vivo generated human CAR T cells eradicate tumor cells". OncoImmunology. 8 (12): e1671761. doi:10.1080/2162402x.2019.1671761. ISSN 2162-402X. PMC 6844313. PMID 31741773.
Agarwalla, Pritha; Ogunnaike, Edikan A.; Ahn, Sarah; Froehlich, Kristen A.; Jansson, Anton; Ligler, Frances S.; Dotti, Gianpietro; Brudno, Yevgeny (2022-03-24). "Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells". Nature Biotechnology. 40 (8): 1250–1258. doi:10.1038/s41587-022-01245-x. ISSN 1087-0156. PMC 9376243. PMID 35332339.
Ghassemi, Saba; Durgin, Joseph S.; Nunez-Cruz, Selene; Patel, Jai; Leferovich, John; Pinzone, Marilia; Shen, Feng; Cummins, Katherine D.; Plesa, Gabriela; Cantu, Vito Adrian; Reddy, Shantan; Bushman, Frederic D.; Gill, Saar I.; O'Doherty, Una; O'Connor, Roddy S. (February 2022). "Rapid manufacturing of non-activated potent CAR T cells". Nature Biomedical Engineering. 6 (2): 118–128. doi:10.1038/s41551-021-00842-6. ISSN 2157-846X. PMC 8860360. PMID 35190680.
Ledford, Heidi (2023-12-20). "Cancer-fighting CAR-T cells could be made inside body with viral injection". Nature. 625 (7994): 225–226. doi:10.1038/d41586-023-03969-5. PMID 38129613.
Chakraborty, Samik; Ye, Juan; Wang, Herui; Sun, Mitchell; Zhang, Yaping; Sang, Xueyu; Zhuang, Zhengping (2023-10-23). "Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy". Frontiers in Immunology. 14. doi:10.3389/fimmu.2023.1227833. ISSN 1664-3224. PMC 10626551. PMID 37936697.
Mikolič, Veronika; Pantović-Žalig, Jelica; Malenšek, Špela; Sever, Matjaž; Lainšček, Duško; Jerala, Roman (June 2024). "Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors". Molecular Therapy: Oncology. 32 (2): 200815. doi:10.1016/j.omton.2024.200815. ISSN 2950-3299. PMC 11152746. PMID 38840781.
Wu, Ling; Brzostek, Joanna; Sakthi Vale, Previtha Dawn; Wei, Qianru; Koh, Clara K. T.; Ong, June Xu Hui; Wu, Liang-Zhe; Tan, Jia Chi; Chua, Yen Leong; Yap, Jiawei; Song, Yuan; Tan, Vivian Jia Yi; Tan, Triscilla Y. Y.; Lai, Junyun; MacAry, Paul A. (2023-02-21). "CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance". Cell Reports. Medicine. 4 (2): 100917. doi:10.1016/j.xcrm.2023.100917. ISSN 2666-3791. PMC 9975250. PMID 36696897.
Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi; Bhoj, Vijay; Gershenson, Zack; Moon, Edmund; Newick, Kheng; Sun, Jing; Lo, Albert; Baradet, Timothy; Feldman, Michael D.; Barrett, David; Puré, Ellen; Albelda, Steven; Milone, Michael C. (July 2015). "Generation of Potent T-cell Immunotherapy for Cancer using DAP12-based, Multichain, Chimeric Immunoreceptors". Cancer Immunology Research. 3 (7): 815–826. doi:10.1158/2326-6066.CIR-15-0054. ISSN 2326-6066. PMC 4490943. PMID 25941351.
Prinzing, Brooke; Schreiner, Patrick; Bell, Matthew; Fan, Yiping; Krenciute, Giedre; Gottschalk, Stephen (2020-11-05). "MyD88/CD40 signaling retains CAR T cells in a less differentiated state". JCI Insight. 5 (21): e136093, 136093. doi:10.1172/jci.insight.136093. ISSN 2379-3708. PMC 7710311. PMID 33148882.
Collinson-Pautz, Matthew R.; Chang, Wei-Chun; Lu, An; Khalil, Mariam; Crisostomo, Jeannette W.; Lin, Pei-Yi; Mahendravada, Aruna; Shinners, Nicholas P.; Brandt, Mary E.; Zhang, Ming; Duong, MyLinh; Bayle, J. Henri; Slawin, Kevin M.; Spencer, David M.; Foster, Aaron E. (September 2019). "Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies". Leukemia. 33 (9): 2195–2207. doi:10.1038/s41375-019-0417-9. ISSN 1476-5551. PMC 6756044. PMID 30816327.
Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA (September 2020). "Value and affordability of CAR T-cell therapy in the United States". Bone Marrow Transplantation. 55 (9): 1706–1715. doi:10.1038/s41409-020-0956-8. PMID 32474570. S2CID 218987876.

ncbi.nlm.nih.gov

Srivastava S, Riddell SR (August 2015). "Engineering CAR-T cells: Design concepts". Trends in Immunology. 36 (8): 494–502. doi:10.1016/j.it.2015.06.004. PMC 4746114. PMID 26169254.
Sadelain M, Brentjens R, Rivière I (April 2013). "The basic principles of chimeric antigen receptor design". Cancer Discovery. 3 (4): 388–398. doi:10.1158/2159-8290.CD-12-0548. PMC 3667586. PMID 23550147.
Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ (September 2017). "Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts". EMBO Molecular Medicine. 9 (9): 1183–1197. doi:10.15252/emmm.201607485. PMC 5582407. PMID 28765140.
Tang XJ, Sun XY, Huang KM, Zhang L, Yang ZS, Zou DD, et al. (December 2015). "Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy". Oncotarget. 6 (42): 44179–44190. doi:10.18632/oncotarget.6175. PMC 4792550. PMID 26496034.
Zhang H, Zhao P, Huang H (December 2020). "Engineering better chimeric antigen receptor T cells". Experimental Hematology & Oncology. 9 (1): 34. doi:10.1186/s40164-020-00190-2. PMC 7709221. PMID 33292660.
Gross G, Waks T, Eshhar Z (December 1989). "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity". Proceedings of the National Academy of Sciences of the United States of America. 86 (24): 10024–10028. Bibcode:1989PNAS...8610024G. doi:10.1073/pnas.86.24.10024. JSTOR 34790. PMC 298636. PMID 2513569.
June CH, Sadelain M (July 2018). "Chimeric Antigen Receptor Therapy". The New England Journal of Medicine. 379 (1): 64–73. doi:10.1056/NEJMra1706169. PMC 7433347. PMID 29972754.
Braendstrup P, Levine BL, Ruella M (February 2020). "The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19". Cytotherapy. 22 (2): 57–69. doi:10.1016/j.jcyt.2019.12.004. PMC 7036015. PMID 32014447.
Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M (2014-03-05). "Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors". Molecular Therapy: Methods & Clinical Development. 1: 14001. doi:10.1038/mtm.2014.1. PMC 4362340. PMID 26015949.
Makita S, Yoshimura K, Tobinai K (June 2017). "Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma". Cancer Science. 108 (6): 1109–1118. doi:10.1111/cas.13239. PMC 5480083. PMID 28301076.
Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D (July 2016). "Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer". EMBO Molecular Medicine. 8 (7): 702–711. doi:10.15252/emmm.201505869. PMC 4931286. PMID 27189167.
Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP (December 2006). "Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?". Nature Clinical Practice. Oncology. 3 (12): 668–681. doi:10.1038/ncponc0666. PMC 1773008. PMID 17139318.
Almåsbak H, Aarvak T, Vemuri MC (2016). "CAR T Cell Therapy: A Game Changer in Cancer Treatment". Journal of Immunology Research. 2016: 5474602. doi:10.1155/2016/5474602. PMC 4889848. PMID 27298832.
Li, Nan; Spetz, Madeline R.; Li, Dan; Ho, Mitchell (July 2021). "Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3". Pharmacology & Therapeutics. 223: 107892. doi:10.1016/j.pharmthera.2021.107892. ISSN 1879-016X. PMC 8202769. PMID 33992682.
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. (November 2010). "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19". Blood. 116 (20): 4099–4102. doi:10.1182/blood-2010-04-281931. PMC 2993617. PMID 20668228.
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. (February 2015). "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor". Journal of Clinical Oncology. 33 (6): 540–549. doi:10.1200/JCO.2014.56.2025. PMC 4322257. PMID 25154820.
Choi, Bryan D.; Gerstner, Elizabeth R.; Frigault, Matthew J.; Leick, Mark B.; Mount, Christopher W.; Balaj, Leonora; Nikiforow, Sarah; Carter, Bob S.; Curry, William T.; Gallagher, Kathleen; Maus, Marcela V. (2024-04-11). "Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma". New England Journal of Medicine. 390 (14): 1290–1298. doi:10.1056/NEJMoa2314390. ISSN 0028-4793. PMC 11162836. PMID 38477966.
Lim WA, June CH (February 2017). "The Principles of Engineering Immune Cells to Treat Cancer". Cell. 168 (4): 724–740. doi:10.1016/j.cell.2017.01.016. PMC 5553442. PMID 28187291.
Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, et al. (June 2020). "Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice". Gastroenterology. 158 (8): 2250–2265.e20. doi:10.1053/j.gastro.2020.02.011. PMC 7282931. PMID 32060001.
Li, Nan; Fu, Haiying; Hewitt, Stephen M.; Dimitrov, Dimiter S.; Ho, Mitchell (2017-08-08). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America. 114 (32): E6623–E6631. Bibcode:2017PNAS..114E6623L. doi:10.1073/pnas.1706055114. ISSN 1091-6490. PMC 5559039. PMID 28739923.
Li, Nan; Torres, Madeline B.; Spetz, Madeline R.; Wang, Ruixue; Peng, Luyi; Tian, Meijie; Dower, Christopher M.; Nguyen, Rosa; Sun, Ming; Tai, Chin-Hsien; de Val, Natalia; Cachau, Raul; Wu, Xiaolin; Hewitt, Stephen M.; Kaplan, Rosandra N. (2021-06-15). "CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice". Cell Reports. Medicine. 2 (6): 100297. doi:10.1016/j.xcrm.2021.100297. ISSN 2666-3791. PMC 8233664. PMID 34195677.
Zhang Q, Lu W, Liang CL, Chen Y, Liu H, Qiu F, Dai Z (2018). "Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance". Frontiers in Immunology. 9: 2359. doi:10.3389/fimmu.2018.02359. PMC 6194362. PMID 30369931.
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016). "Toxicity and management in CAR T-cell therapy". Molecular Therapy: Oncolytics. 3: 16011. doi:10.1038/mto.2016.11. PMC 5008265. PMID 27626062.
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. (July 2014). "Current concepts in the diagnosis and management of cytokine release syndrome". Blood. 124 (2): 188–195. doi:10.1182/blood-2014-05-552729. PMC 4093680. PMID 24876563.
Berg P, Schönefeld S, Ruppert-Seipp G, Funk MB (2022-11-29). "Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment". Transfusion Medicine and Hemotherapy. 50 (3): 218–225. doi:10.1159/000526786. ISSN 1660-3796. PMC 10331154. PMID 37435000.
Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, et al. (December 2019). "Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy". Blood. 134 (24): 2149–2158. doi:10.1182/blood.2019001463. PMC 6908832. PMID 31697826.
Tan AH, Vinanica N, Campana D (April 2020). "Chimeric antigen receptor-T cells with cytokine neutralizing capacity". Blood advances. 4 (7): 1419–1431. doi:10.1182/bloodadvances.2019001287. PMC 7160280. PMID 32271901.
Brudno JN, Kochenderfer JN (June 2016). "Toxicities of chimeric antigen receptor T cells: recognition and management". Blood. 127 (26): 3321–3330. doi:10.1182/blood-2016-04-703751. PMC 4929924. PMID 27207799.
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. (June 2016). "CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients". The Journal of Clinical Investigation. 126 (6): 2123–2138. doi:10.1172/JCI85309. PMC 4887159. PMID 27111235.
Chandran SS, Klebanoff CA (July 2019). "T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance". Immunological Reviews. 290 (1): 127–147. doi:10.1111/imr.12772. PMC 7027847. PMID 31355495. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Dotti G, Gottschalk S, Savoldo B, Brenner MK (January 2014). "Design and development of therapies using chimeric antigen receptor-expressing T cells". Immunological Reviews. 257 (1): 107–126. doi:10.1111/imr.12131. PMC 3874724. PMID 24329793.
Zhang C, Liu J, Zhong JF, Zhang X (2017-06-24). "Engineering CAR-T cells". Biomarker Research. 5: 22. doi:10.1186/s40364-017-0102-y. PMC 5482931. PMID 28652918.
Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M (August 2017). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America. 114 (32): E6623–E6631. Bibcode:2017PNAS..114E6623L. doi:10.1073/pnas.1706055114. PMC 5559039. PMID 28739923.
Li, Nan; Quan, Alex; Li, Dan; Pan, Jiajia; Ren, Hua; Hoeltzel, Gerard; de Val, Natalia; Ashworth, Dana; Ni, Weiming; Zhou, Jing; Mackay, Sean; Hewitt, Stephen M.; Cachau, Raul; Ho, Mitchell (2023-04-08). "The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer". Nature Communications. 14 (1): 1986. Bibcode:2023NatCo..14.1986L. doi:10.1038/s41467-023-37616-4. ISSN 2041-1723. PMC 10082787. PMID 37031249.
Kolluri, Aarti; Li, Dan; Li, Nan; Duan, Zhijian; Roberts, Lewis R.; Ho, Mitchell (2023-02-01). "Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC". Hepatology Communications. 7 (2): e0022. doi:10.1097/HC9.0000000000000022. ISSN 2471-254X. PMC 9851680. PMID 36691969.
Li, Dan; English, Hejiao; Hong, Jessica; Liang, Tianyuzhou; Merlino, Glenn; Day, Chi-Ping; Ho, Mitchell (2022-03-17). "A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer". Molecular Therapy: Oncolytics. 24: 849–863. doi:10.1016/j.omto.2022.02.015. ISSN 2372-7705. PMC 8917269. PMID 35317524.
Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. (February 2015). "The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity". Cancer Immunology Research. 3 (2): 125–135. doi:10.1158/2326-6066.CIR-14-0127. PMC 4692801. PMID 25212991.
Qin L, Lai Y, Zhao R, Wei X, Weng J, Lai P, et al. (March 2017). "Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells". Journal of Hematology & Oncology. 10 (1): 68. doi:10.1186/s13045-017-0437-8. PMC 5347831. PMID 28288656.
Casucci M, Bondanza A (2011). "Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes". Journal of Cancer. 2: 378–382. doi:10.7150/jca.2.378. PMC 3133962. PMID 21750689.
Cho JH, Collins JJ, Wong WW (May 2018). "Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses". Cell. 173 (6): 1426–1438.e11. doi:10.1016/j.cell.2018.03.038. PMC 5984158. PMID 29706540.
Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE (March 2018). "CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity". Molecular Therapy: Oncolytics. 8: 41–51. doi:10.1016/j.omto.2017.12.003. PMC 5772011. PMID 29367945.
Zhang E, Xu H (January 2017). "A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy". Journal of Hematology & Oncology. 10 (1): 1. doi:10.1186/s13045-016-0379-6. PMC 5210295. PMID 28049484.
Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, et al. (October 2007). "Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes". Blood. 110 (8): 2793–2802. doi:10.1182/blood-2007-02-072843. PMC 2018664. PMID 17638856.
Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA (October 2015). "Remote control of therapeutic T cells through a small molecule-gated chimeric receptor". Science. 350 (6258): aab4077. Bibcode:2015Sci...350.4077W. doi:10.1126/science.aab4077. PMC 4721629. PMID 26405231.
Kim CH, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, et al. (October 2013). "Bispecific small molecule-antibody conjugate targeting prostate cancer". Proceedings of the National Academy of Sciences of the United States of America. 110 (44): 17796–17801. Bibcode:2013PNAS..11017796K. doi:10.1073/pnas.1316026110. PMC 3816437. PMID 24127589.
Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC (April 2020). "Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma". JAMA Network Open. 3 (4): e202072. doi:10.1001/jamanetworkopen.2020.2072. PMC 7136832. PMID 32250433.
Smith, Tyrel T.; Stephan, Sirkka B.; Moffett, Howell F.; McKnight, Laura E.; Ji, Weihang; Reiman, Diana; Bonagofski, Emmy; Wohlfahrt, Martin E.; Pillai, Smitha P. S.; Stephan, Matthias T. (2017-04-17). "In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers". Nature Nanotechnology. 12 (8): 813–820. doi:10.1038/nnano.2017.57. ISSN 1748-3387. PMC 5646367. PMID 28416815.
Agarwal, Shiwani; Weidner, Tatjana; Thalheimer, Frederic B.; Buchholz, Christian J. (2019-10-10). "In vivo generated human CAR T cells eradicate tumor cells". OncoImmunology. 8 (12): e1671761. doi:10.1080/2162402x.2019.1671761. ISSN 2162-402X. PMC 6844313. PMID 31741773.
Agarwalla, Pritha; Ogunnaike, Edikan A.; Ahn, Sarah; Froehlich, Kristen A.; Jansson, Anton; Ligler, Frances S.; Dotti, Gianpietro; Brudno, Yevgeny (2022-03-24). "Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells". Nature Biotechnology. 40 (8): 1250–1258. doi:10.1038/s41587-022-01245-x. ISSN 1087-0156. PMC 9376243. PMID 35332339.
Ghassemi, Saba; Durgin, Joseph S.; Nunez-Cruz, Selene; Patel, Jai; Leferovich, John; Pinzone, Marilia; Shen, Feng; Cummins, Katherine D.; Plesa, Gabriela; Cantu, Vito Adrian; Reddy, Shantan; Bushman, Frederic D.; Gill, Saar I.; O'Doherty, Una; O'Connor, Roddy S. (February 2022). "Rapid manufacturing of non-activated potent CAR T cells". Nature Biomedical Engineering. 6 (2): 118–128. doi:10.1038/s41551-021-00842-6. ISSN 2157-846X. PMC 8860360. PMID 35190680.
Chakraborty, Samik; Ye, Juan; Wang, Herui; Sun, Mitchell; Zhang, Yaping; Sang, Xueyu; Zhuang, Zhengping (2023-10-23). "Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy". Frontiers in Immunology. 14. doi:10.3389/fimmu.2023.1227833. ISSN 1664-3224. PMC 10626551. PMID 37936697.
Mikolič, Veronika; Pantović-Žalig, Jelica; Malenšek, Špela; Sever, Matjaž; Lainšček, Duško; Jerala, Roman (June 2024). "Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors". Molecular Therapy: Oncology. 32 (2): 200815. doi:10.1016/j.omton.2024.200815. ISSN 2950-3299. PMC 11152746. PMID 38840781.
Wu, Ling; Brzostek, Joanna; Sakthi Vale, Previtha Dawn; Wei, Qianru; Koh, Clara K. T.; Ong, June Xu Hui; Wu, Liang-Zhe; Tan, Jia Chi; Chua, Yen Leong; Yap, Jiawei; Song, Yuan; Tan, Vivian Jia Yi; Tan, Triscilla Y. Y.; Lai, Junyun; MacAry, Paul A. (2023-02-21). "CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance". Cell Reports. Medicine. 4 (2): 100917. doi:10.1016/j.xcrm.2023.100917. ISSN 2666-3791. PMC 9975250. PMID 36696897.
Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi; Bhoj, Vijay; Gershenson, Zack; Moon, Edmund; Newick, Kheng; Sun, Jing; Lo, Albert; Baradet, Timothy; Feldman, Michael D.; Barrett, David; Puré, Ellen; Albelda, Steven; Milone, Michael C. (July 2015). "Generation of Potent T-cell Immunotherapy for Cancer using DAP12-based, Multichain, Chimeric Immunoreceptors". Cancer Immunology Research. 3 (7): 815–826. doi:10.1158/2326-6066.CIR-15-0054. ISSN 2326-6066. PMC 4490943. PMID 25941351.
Prinzing, Brooke; Schreiner, Patrick; Bell, Matthew; Fan, Yiping; Krenciute, Giedre; Gottschalk, Stephen (2020-11-05). "MyD88/CD40 signaling retains CAR T cells in a less differentiated state". JCI Insight. 5 (21): e136093, 136093. doi:10.1172/jci.insight.136093. ISSN 2379-3708. PMC 7710311. PMID 33148882.
Collinson-Pautz, Matthew R.; Chang, Wei-Chun; Lu, An; Khalil, Mariam; Crisostomo, Jeannette W.; Lin, Pei-Yi; Mahendravada, Aruna; Shinners, Nicholas P.; Brandt, Mary E.; Zhang, Ming; Duong, MyLinh; Bayle, J. Henri; Slawin, Kevin M.; Spencer, David M.; Foster, Aaron E. (September 2019). "Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies". Leukemia. 33 (9): 2195–2207. doi:10.1038/s41375-019-0417-9. ISSN 1476-5551. PMC 6756044. PMID 30816327.

novartis.com

"Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice". www.novartis.com. 2017-08-30.
"Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)". www.novartis.com. Retrieved 2023-11-18.
"FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma". Novartis. Retrieved 2022-06-05.
"Novartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma". www.novartis.com. Retrieved 2023-11-18.

reuters.com

"Novartis gets approval to sell Kymriah in Japan for $306,000". www.reuters.com. 2019-05-15.

semanticscholar.org

api.semanticscholar.org

Rosenbaum L (October 2017). "Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy". The New England Journal of Medicine. 377 (14): 1313–1315. doi:10.1056/NEJMp1711886. PMID 28902570. S2CID 205114161.
Eshhar Z, Bach N, Fitzer-Attas CJ, Gross G, Lustgarten J, Waks T, Schindler DG (1996). "The T-body approach: potential for cancer immunotherapy". Springer Seminars in Immunopathology. 18 (2): 199–209. doi:10.1007/BF00820666. PMID 8908700. S2CID 19872173.
Irving BA, Weiss A (March 1991). "The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways". Cell. 64 (5): 891–901. doi:10.1016/0092-8674(91)90314-o. PMID 1705867. S2CID 23466990.
Sadelain M, Rivière I, Brentjens R (January 2003). "Targeting tumours with genetically enhanced T lymphocytes". Nature Reviews. Cancer. 3 (1): 35–45. doi:10.1038/nrc971. PMID 12509765. S2CID 33707802.
Li, Nan; Ho, Mitchell (2022). "Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma". Single-Domain Antibodies. Methods in Molecular Biology. Vol. 2446. pp. 451–468. doi:10.1007/978-1-0716-2075-5_23. ISBN 978-1-0716-2074-8. ISSN 1940-6029. PMID 35157288. S2CID 246813053.
Xin Yu J, Hubbard-Lucey VM, Tang J (October 2019). "The global pipeline of cell therapies for cancer". Nature Reviews. Drug Discovery. 18 (11): 821–822. doi:10.1038/d41573-019-00090-z. PMID 31673124. S2CID 190862546.
Li, Dan; Lin, Shaoli; Hong, Jessica; Ho, Mitchell (2022). "Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances". Advances in Cancer Research. 156: 415–449. doi:10.1016/bs.acr.2022.01.013. ISBN 9780323983921. ISSN 2162-5557. PMID 35961708. S2CID 246978004.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M (May 2008). "Regulatory T cells and immune tolerance". Cell. 133 (5): 775–787. doi:10.1016/j.cell.2008.05.009. PMID 18510923. S2CID 2315895.
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. (August 2021). "CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus". The New England Journal of Medicine. 385 (6): 567–569. doi:10.1056/NEJMc2107725. PMID 34347960. S2CID 236927691.
Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B (June 2021). "CAR-T cell therapy and infection: a review". Expert Review of Anti-Infective Therapy. 19 (6): 749–758. doi:10.1080/14787210.2021.1855143. PMID 33249873. S2CID 227235627.
Breslin S (February 2007). "Cytokine-release syndrome: overview and nursing implications". Clinical Journal of Oncology Nursing. 11 (1 Suppl): 37–42. doi:10.1188/07.CJON.S1.37-42. PMID 17471824. S2CID 35773028.
Baldo BA (May 2015). "Chimeric fusion proteins used for therapy: indications, mechanisms, and safety". Drug Safety. 38 (5): 455–479. doi:10.1007/s40264-015-0285-9. PMID 25832756. S2CID 23852865.
Chmielewski M, Abken H (2015). "TRUCKs: the fourth generation of CARs". Expert Opinion on Biological Therapy. 15 (8): 1145–1154. doi:10.1517/14712598.2015.1046430. PMID 25985798. S2CID 42535203.
Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, et al. (February 1996). "T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients". Nature Medicine. 2 (2): 216–223. doi:10.1038/nm0296-216. PMID 8574968. S2CID 35503876.
Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M (January 2002). "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor". Nature Biotechnology. 20 (1): 70–75. doi:10.1038/nbt0102-70. PMID 11753365. S2CID 20302096.
Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. (October 2012). "Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling". Journal of Clinical Immunology. 32 (5): 1059–1070. doi:10.1007/s10875-012-9689-9. PMID 22526592. S2CID 17660404.
Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, et al. (May 2015). "Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies". Science Translational Medicine. 7 (287): 287ra70. doi:10.1126/scitranslmed.aaa4802. PMID 25972002. S2CID 24939667.
Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA (September 2020). "Value and affordability of CAR T-cell therapy in the United States". Bone Marrow Transplantation. 55 (9): 1706–1715. doi:10.1038/s41409-020-0956-8. PMID 32474570. S2CID 218987876.

susupport.com

Eder M (25 November 2021). "Which countries is CAR T-cell therapy available in? | SingleUseSupport". Retrieved 13 May 2022.

web.archive.org

SMDC technology. Archived 2016-03-27 at the Wayback Machine ENDOCYTE
"Endocyte announces promising preclinical data for application of SMDC technology in CAR T cell therapy in late-breaking abstract at American Association for Cancer Research (AACR) annual meeting 2016" (Press release). Endocyte. April 19, 2016. Archived from the original on July 30, 2017. Retrieved December 20, 2017.
"CAR T-cell Therapy: An Update on Coverage and Reimbursement - Hematology.org". www.hematology.org. Archived from the original on 2022-01-24. Retrieved 2021-03-22.

worldcat.org

search.worldcat.org

Li, Nan; Ho, Mitchell (2022). "Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma". Single-Domain Antibodies. Methods in Molecular Biology. Vol. 2446. pp. 451–468. doi:10.1007/978-1-0716-2075-5_23. ISBN 978-1-0716-2074-8. ISSN 1940-6029. PMID 35157288. S2CID 246813053.
Li, Nan; Spetz, Madeline R.; Li, Dan; Ho, Mitchell (July 2021). "Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3". Pharmacology & Therapeutics. 223: 107892. doi:10.1016/j.pharmthera.2021.107892. ISSN 1879-016X. PMC 8202769. PMID 33992682.
Li, Dan; Lin, Shaoli; Hong, Jessica; Ho, Mitchell (2022). "Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances". Advances in Cancer Research. 156: 415–449. doi:10.1016/bs.acr.2022.01.013. ISBN 9780323983921. ISSN 2162-5557. PMID 35961708. S2CID 246978004.
Choi, Bryan D.; Gerstner, Elizabeth R.; Frigault, Matthew J.; Leick, Mark B.; Mount, Christopher W.; Balaj, Leonora; Nikiforow, Sarah; Carter, Bob S.; Curry, William T.; Gallagher, Kathleen; Maus, Marcela V. (2024-04-11). "Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma". New England Journal of Medicine. 390 (14): 1290–1298. doi:10.1056/NEJMoa2314390. ISSN 0028-4793. PMC 11162836. PMID 38477966.
Li, Nan; Fu, Haiying; Hewitt, Stephen M.; Dimitrov, Dimiter S.; Ho, Mitchell (2017-08-08). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America. 114 (32): E6623–E6631. Bibcode:2017PNAS..114E6623L. doi:10.1073/pnas.1706055114. ISSN 1091-6490. PMC 5559039. PMID 28739923.
Li, Nan; Torres, Madeline B.; Spetz, Madeline R.; Wang, Ruixue; Peng, Luyi; Tian, Meijie; Dower, Christopher M.; Nguyen, Rosa; Sun, Ming; Tai, Chin-Hsien; de Val, Natalia; Cachau, Raul; Wu, Xiaolin; Hewitt, Stephen M.; Kaplan, Rosandra N. (2021-06-15). "CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice". Cell Reports. Medicine. 2 (6): 100297. doi:10.1016/j.xcrm.2021.100297. ISSN 2666-3791. PMC 8233664. PMID 34195677.
Berg P, Schönefeld S, Ruppert-Seipp G, Funk MB (2022-11-29). "Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment". Transfusion Medicine and Hemotherapy. 50 (3): 218–225. doi:10.1159/000526786. ISSN 1660-3796. PMC 10331154. PMID 37435000.
Li, Nan; Quan, Alex; Li, Dan; Pan, Jiajia; Ren, Hua; Hoeltzel, Gerard; de Val, Natalia; Ashworth, Dana; Ni, Weiming; Zhou, Jing; Mackay, Sean; Hewitt, Stephen M.; Cachau, Raul; Ho, Mitchell (2023-04-08). "The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer". Nature Communications. 14 (1): 1986. Bibcode:2023NatCo..14.1986L. doi:10.1038/s41467-023-37616-4. ISSN 2041-1723. PMC 10082787. PMID 37031249.
Kolluri, Aarti; Li, Dan; Li, Nan; Duan, Zhijian; Roberts, Lewis R.; Ho, Mitchell (2023-02-01). "Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC". Hepatology Communications. 7 (2): e0022. doi:10.1097/HC9.0000000000000022. ISSN 2471-254X. PMC 9851680. PMID 36691969.
Li, Dan; English, Hejiao; Hong, Jessica; Liang, Tianyuzhou; Merlino, Glenn; Day, Chi-Ping; Ho, Mitchell (2022-03-17). "A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer". Molecular Therapy: Oncolytics. 24: 849–863. doi:10.1016/j.omto.2022.02.015. ISSN 2372-7705. PMC 8917269. PMID 35317524.
Smith, Tyrel T.; Stephan, Sirkka B.; Moffett, Howell F.; McKnight, Laura E.; Ji, Weihang; Reiman, Diana; Bonagofski, Emmy; Wohlfahrt, Martin E.; Pillai, Smitha P. S.; Stephan, Matthias T. (2017-04-17). "In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers". Nature Nanotechnology. 12 (8): 813–820. doi:10.1038/nnano.2017.57. ISSN 1748-3387. PMC 5646367. PMID 28416815.
Agarwal, Shiwani; Weidner, Tatjana; Thalheimer, Frederic B.; Buchholz, Christian J. (2019-10-10). "In vivo generated human CAR T cells eradicate tumor cells". OncoImmunology. 8 (12): e1671761. doi:10.1080/2162402x.2019.1671761. ISSN 2162-402X. PMC 6844313. PMID 31741773.
Agarwalla, Pritha; Ogunnaike, Edikan A.; Ahn, Sarah; Froehlich, Kristen A.; Jansson, Anton; Ligler, Frances S.; Dotti, Gianpietro; Brudno, Yevgeny (2022-03-24). "Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells". Nature Biotechnology. 40 (8): 1250–1258. doi:10.1038/s41587-022-01245-x. ISSN 1087-0156. PMC 9376243. PMID 35332339.
Ghassemi, Saba; Durgin, Joseph S.; Nunez-Cruz, Selene; Patel, Jai; Leferovich, John; Pinzone, Marilia; Shen, Feng; Cummins, Katherine D.; Plesa, Gabriela; Cantu, Vito Adrian; Reddy, Shantan; Bushman, Frederic D.; Gill, Saar I.; O'Doherty, Una; O'Connor, Roddy S. (February 2022). "Rapid manufacturing of non-activated potent CAR T cells". Nature Biomedical Engineering. 6 (2): 118–128. doi:10.1038/s41551-021-00842-6. ISSN 2157-846X. PMC 8860360. PMID 35190680.
Chakraborty, Samik; Ye, Juan; Wang, Herui; Sun, Mitchell; Zhang, Yaping; Sang, Xueyu; Zhuang, Zhengping (2023-10-23). "Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy". Frontiers in Immunology. 14. doi:10.3389/fimmu.2023.1227833. ISSN 1664-3224. PMC 10626551. PMID 37936697.
Mikolič, Veronika; Pantović-Žalig, Jelica; Malenšek, Špela; Sever, Matjaž; Lainšček, Duško; Jerala, Roman (June 2024). "Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors". Molecular Therapy: Oncology. 32 (2): 200815. doi:10.1016/j.omton.2024.200815. ISSN 2950-3299. PMC 11152746. PMID 38840781.
Chen, Xue; Zhang, Yunxiao; Fu, Yao (2022-06-01). "The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy". Medicine in Drug Discovery. 14: 100122. doi:10.1016/j.medidd.2022.100122. ISSN 2590-0986.
Wu, Ling; Brzostek, Joanna; Sakthi Vale, Previtha Dawn; Wei, Qianru; Koh, Clara K. T.; Ong, June Xu Hui; Wu, Liang-Zhe; Tan, Jia Chi; Chua, Yen Leong; Yap, Jiawei; Song, Yuan; Tan, Vivian Jia Yi; Tan, Triscilla Y. Y.; Lai, Junyun; MacAry, Paul A. (2023-02-21). "CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance". Cell Reports. Medicine. 4 (2): 100917. doi:10.1016/j.xcrm.2023.100917. ISSN 2666-3791. PMC 9975250. PMID 36696897.
Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi; Bhoj, Vijay; Gershenson, Zack; Moon, Edmund; Newick, Kheng; Sun, Jing; Lo, Albert; Baradet, Timothy; Feldman, Michael D.; Barrett, David; Puré, Ellen; Albelda, Steven; Milone, Michael C. (July 2015). "Generation of Potent T-cell Immunotherapy for Cancer using DAP12-based, Multichain, Chimeric Immunoreceptors". Cancer Immunology Research. 3 (7): 815–826. doi:10.1158/2326-6066.CIR-15-0054. ISSN 2326-6066. PMC 4490943. PMID 25941351.
"152. A Chimeric Antigen Receptor (CARs) Based Upon a Killer Immunoglobulin-Like Receptor (KIR) Triggers Robust Cytotoxic Activity in Solid Tumors". Molecular Therapy. 22: S57. May 2014. doi:10.1016/s1525-0016(16)35165-6. ISSN 1525-0016.
Xu, Jun; Nunez-Cruz, Selene; Leferovich, John M.; Gulendran, Gayathri; Zhang, Chune; Yucel, Nora D.; Blair, Megan C.; Stanley, William S.; Johnson, Laura A.; Siegel, Don L.; Milone, Michael C. (2024-03-22). "Abstract 6332: Evaluating the relationship of affinity, functional avidity, and in vivo potency in KIR-CAR T cells". Cancer Research. 84 (6_Supplement): 6332. doi:10.1158/1538-7445.AM2024-6332. ISSN 1538-7445.
Prinzing, Brooke; Schreiner, Patrick; Bell, Matthew; Fan, Yiping; Krenciute, Giedre; Gottschalk, Stephen (2020-11-05). "MyD88/CD40 signaling retains CAR T cells in a less differentiated state". JCI Insight. 5 (21): e136093, 136093. doi:10.1172/jci.insight.136093. ISSN 2379-3708. PMC 7710311. PMID 33148882.
Collinson-Pautz, Matthew R.; Chang, Wei-Chun; Lu, An; Khalil, Mariam; Crisostomo, Jeannette W.; Lin, Pei-Yi; Mahendravada, Aruna; Shinners, Nicholas P.; Brandt, Mary E.; Zhang, Ming; Duong, MyLinh; Bayle, J. Henri; Slawin, Kevin M.; Spencer, David M.; Foster, Aaron E. (September 2019). "Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies". Leukemia. 33 (9): 2195–2207. doi:10.1038/s41375-019-0417-9. ISSN 1476-5551. PMC 6756044. PMID 30816327.